{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:34Z","timestamp":1792190494403,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shandong Provincial Traditional Chinese Medicine Science and Technology Project","award":["M20244301"],"award-info":[{"award-number":["M20244301"]}]},{"name":"Research and Development Fund Project of Affiliated Hospital of Shandong Second Medical University","award":["2024FYM024"],"award-info":[{"award-number":["2024FYM024"]}]},{"name":"Research and Innovation Project of Affiliated Hospital of Weifang Medical University","award":["2022BSQD07"],"award-info":[{"award-number":["2022BSQD07"]}]},{"name":"Science and Technology Development Plan of Weifang in 2022","award":["2022YX026"],"award-info":[{"award-number":["2022YX026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T cell immunoglobulin and mucin-domain containing protein 3 (TIM-3) is an immune checkpoint that plays a crucial role in immune exhaustion. High expression of TIM-3 has been implicated in exerting immunosuppression across a variety of malignant tumors. Elucidating the expression profile of TIM-3 and its prognostic impact may hold great significance for the therapeutic management of intrahepatic cholangiocarcinoma (ICC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 117 ICC patients using immunohistochemical staining for TIM-3 and other immune checkpoints to examined their expression and immune cell infiltration in ICC tissue samples. Furthermore, the correlation of checkpoint expression with clinical characteristics and prognosis were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High expression of TIM-3 in tumor cells was observed in 61 patients (52.1%) and was significantly correlated with poorer tumor differentiation (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.019). Survival analysis showed that high TIM-3 expression in tumor cells was a prognostic factor for disease-free survival (DFS) and overall survival (OS) in univariate analysis, and an independent risk predictor for DFS in multivariate analysis (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.048, HR\u2009=\u20091.589, 95%CI\u2009=\u20091.004\u20132.515). Furthermore, TIM-3 expression in ICC tissues was significantly correlated with CD4\u207a and CD8\u207a tumor-infiltrating lymphocytes (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with high TIM-3 expression in tumor cells had shorter DFS and OS, which could serve as a valuable biomarker for predicting the inflammatory status and prognosis of ICC. Targeting TIM-3 may represent a promising therapeutic strategy for ICC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16292-9","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:05:19Z","timestamp":1780621519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The expression status and clinical value of TIM-3 in intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Ziwen","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"16292_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104\u201314.","journal-title":"J Hepatol"},{"key":"16292_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/hbsn.2018.03.16","volume":"7","author":"EW Beal","year":"2018","unstructured":"Beal EW, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2018;7:270\u20136.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"16292_CR3","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77:1690\u20138.","journal-title":"J Hepatol"},{"key":"16292_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"16292_CR5","first-page":"100335","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: And Yet It Moves! Cancer Treat Res Commun. 2021;27:100335.","journal-title":"Cancer Treat Res Commun"},{"key":"16292_CR6","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.2017.14155","volume":"318","author":"SL Topalian","year":"2017","unstructured":"Topalian SL. Targeting Immune Checkpoints in Cancer Therapy. JAMA. 2017;318:1647\u20138.","journal-title":"JAMA"},{"key":"16292_CR7","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig. 2015;125:3384\u201391.","journal-title":"J Clin Investig"},{"key":"16292_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"16292_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2023;401:1853\u201365.","journal-title":"Lancet (London England)"},{"key":"16292_CR10","first-page":"694","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The lancet. Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Gastroenterol Hepatol"},{"key":"16292_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, et al. Cholangiocarcinoma Nat reviews Disease primers. 2021;7:65.","journal-title":"Cholangiocarcinoma Nat reviews Disease primers"},{"key":"16292_CR12","doi-asserted-by":"crossref","unstructured":"Kabut J, Gorzelak-Magiera A, Gisterek-Grocholska I, Targets NT. TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer. Int J Mol Sci 26, (2025).","DOI":"10.3390\/ijms26094096"},{"key":"16292_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","volume":"11","author":"F Liu","year":"2018","unstructured":"Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol. 2018;11:126.","journal-title":"J Hematol Oncol"},{"key":"16292_CR14","first-page":"9452","volume":"8","author":"G Cheng","year":"2015","unstructured":"Cheng G, et al. Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis. Int J Clin Exp Pathol. 2015;8:9452\u20137.","journal-title":"Int J Clin Exp Pathol"},{"key":"16292_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3892\/ol.2020.12330","volume":"21","author":"B Ma","year":"2021","unstructured":"Ma B, et al. High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma. Oncol Lett. 2021;21:69.","journal-title":"Oncol Lett"},{"key":"16292_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-020-06804-6","volume":"20","author":"B Ma","year":"2020","unstructured":"Ma B, et al. Distinct clinical and prognostic implication of IDH1\/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer. 2020;20:318.","journal-title":"BMC Cancer"},{"key":"16292_CR17","doi-asserted-by":"crossref","unstructured":"Heij L et al. Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy. Cells 12, (2023).","DOI":"10.3390\/cells12060851"},{"key":"16292_CR18","doi-asserted-by":"publisher","first-page":"eadp7302","DOI":"10.1126\/sciimmunol.adp7302","volume":"9","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, et al. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci Immunol. 2024;9:eadp7302.","journal-title":"Sci Immunol"},{"key":"16292_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245\u201352.","journal-title":"Nat Immunol"},{"key":"16292_CR20","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","volume":"113","author":"M Nakayama","year":"2009","unstructured":"Nakayama M, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113:3821\u201330.","journal-title":"Blood"},{"key":"16292_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/hep.26938","volume":"59","author":"JS Dolina","year":"2014","unstructured":"Dolina JS, Braciale TJ, Hahn YS. Liver-primed CD8\u2009+\u2009T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology (Baltimore MD). 2014;59:1351\u201365.","journal-title":"Hepatology (Baltimore MD)"},{"key":"16292_CR22","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1038\/s41586-024-07164-y","volume":"626","author":"YH Huang","year":"2024","unstructured":"Huang YH, et al. Author Correction: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2024;626:E19.","journal-title":"Nature"},{"key":"16292_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20:171.","journal-title":"Mol Cancer"},{"key":"16292_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.31092","volume":"72","author":"S Job","year":"2020","unstructured":"Job S, et al. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Hepatology (Baltimore MD). 2020;72:965\u201381.","journal-title":"Hepatology (Baltimore MD)"},{"key":"16292_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, et al. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:349\u201365.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"16292_CR26","doi-asserted-by":"publisher","first-page":"2584667","DOI":"10.1080\/07853890.2025.2584667","volume":"57","author":"Z Yin","year":"2025","unstructured":"Yin Z, Zhang L, Li J, Tan H, Ma B. Research progress on immune checkpoint inhibitors in intrahepatic cholangiocarcinoma. Ann Med. 2025;57:2584667.","journal-title":"Ann Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16292-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16292-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16292-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:11:25Z","timestamp":1786327885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16292-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16292"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16292-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and the Medical Ethics Committee of the Affiliated Hospital of Shandong Second Medical University approved this study (approval no. bc2019026 and no. wyfy-2022-ky-196), and written informed consent was obtained from all patients or their legal guardian.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"950"}}